Torsten O. Nielsen discusses the differences between the PAM50 assay and other approved molecular tests for patients with breast cancer.
Torsten O. Nielsen, MD, PhD, FRCPC, a professor of pathology at the University of British Columbia, discusses the differences between the PAM50 assay and other approved molecular tests for patients with breast cancer.
Most molecular tests, Nielsen says, are very specific for the patient sets from which they were derived and the type of treatment that patients receive. PAM50 is different because it is a biological test that identifies the intrinsic subtypes of breast cancer, Nielsen says. The PAM50 assay is likely to provide relevant information in different types of breast cancer and in different treatment settings.
Nielsen says there are currently clinical trials that are comparing PAM50 with other tests and applying PAM50 to other types of specimens.
SELECT Trial Establishes Lenvatinib’s Role in RAI-Refractory DTC
May 2nd 2024In an interview with Targeted Oncology, Lori J. Wirth, MD, delved into how the data from SELECT signals lenvatinib effectiveness as a frontline therapy for patients with RAI-refractory differentiated thyroid cancer.
Read More
Landgren on MRD as an End Point for Multiple Myeloma Trials
May 1st 2024C. Ola Landgren, MD, PhD, discussed the FDA’s unanimous ODAC vote supporting minimal residual disease as an accelerated approval end point in multiple myeloma and the implications of this vote in the myeloma research field.
Read More